Barclays upgrades Sanofi to "Overweight", stock drops $2.98 due to mixed Phase 3 results.

From Financial Modeling Prep: 2025-07-03 01:00:00

Barclays upgraded Sanofi’s stock grade to “Overweight” but maintains a “hold” action with a revised price target of €115. The company is a global healthcare player focusing on vaccines, rare diseases, and consumer healthcare. Sanofi competes with Pfizer and GlaxoSmithKline, with its stock currently priced at $49.31.

An investigation by Pomerantz LLP is underway following mixed results from Sanofi’s Phase 3 program for itepekimab. The stock has experienced fluctuations, with a recent $0.26 increase, reflecting a 0.53% change. Sanofi’s market capitalization is approximately $120.14 billion, with a trading volume of 1,436,060 shares.

The Phase 3 program results led to a $2.98 drop in Sanofi’s stock, prompting investor concerns. The AERIFY-1 trial met its primary endpoint, but AERIFY-2 did not meet expectations. This has raised questions about the therapy’s future success and its impact on Sanofi’s stock performance. Investors are advised to monitor ongoing developments closely.



Read more at Financial Modeling Prep:: Sanofi (NASDAQ:SNY) Stock Update: Barclays’ New Ra…